Journal article
Identification of the skeletal progenitor cells forming osteophytes in osteoarthritis
Anke J Roelofs, Karolina Kania, Alexandra J Rafipay, Meike Sambale, Stephanie T Kuwahara, Fraser L Collins, Joanna Smeeton, Maxwell A Serowoky, Lynn Rowley, Hui Wang, Rene Gronewold, Chrysa Kapeni, Simon Mendez-Ferrer, Christopher B Little, John F Bateman, Thomas Pap, Francesca Mariani, Joanna Sherwood, J Gage Crump, Cosimo De Bari
Annals of the Rheumatic Diseases | BMJ PUBLISHING GROUP | Published : 2020
Abstract
OBJECTIVES: Osteophytes are highly prevalent in osteoarthritis (OA) and are associated with pain and functional disability. These pathological outgrowths of cartilage and bone typically form at the junction of articular cartilage, periosteum and synovium. The aim of this study was to identify the cells forming osteophytes in OA. METHODS: Fluorescent genetic cell-labelling and tracing mouse models were induced with tamoxifen to switch on reporter expression, as appropriate, followed by surgery to induce destabilisation of the medial meniscus. Contributions of fluorescently labelled cells to osteophytes after 2 or 8 weeks, and their molecular identity, were analysed by histology, immunofluores..
View full abstractGrants
Awarded by Versus Arthritis
Awarded by Medical Research Council
Awarded by Bundesministerium fur Bildung und Forschung (BMBF) Overload-PrevOP consortium
Awarded by Innovative Medizinische Forschung (IMF) Programme of the University Hospital Munster
Awarded by National Insitute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by Wellcome Trust
Awarded by Horizon2020
Awarded by Cancer Research UK
Funding Acknowledgements
CDB, AJRo, KK, AJRa, FLC and HW were supported by funding from Versus Arthritis, formerly Arthritis Research UK (20775, 21156, 20050, 19429), and the Medical Research Council (MR/L020211/1). TP, JSh, MSa and RG were supported by funding from the Bundesministerium fur Bildung und Forschung (BMBF) Overload-PrevOP consortium (01EC1408F) and the Innovative Medizinische Forschung (IMF) Programme of the University Hospital Munster (Project I--SH121608). JGC, STK, JSm, MAS and FVM were supported by funding from the National Insitute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS: R01AR069700). JFB, LR and CBL were supported by the National Health and Medical Research Council (NHMRC: APP1063133), and part funding was provided to JFB by the Victorian Government's Operational Infrastructure Support Programme to the Murdoch Children's Research Institute. CK and SMF were supported by funding from the Wellcome Trust (203151/Z/16/Z), Horizon2020 (ERC-2014--CoG-648765), Cancer Research UK (C61367/A26670) and NHS Blood and Transplant.